Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period) and full yearPrevious forecast published 11 May 2026Because Tabuneos sales deviated significantly from plan in the first quarter, the company analyzed prescription trends and lowered its revenue forecasts for the interim period and full year. In light of the increase in the cost of sales ratio resulting from the decline in Tabuneos sales, the progress and expected expenditure of selling, general and administrative expenses, and the deferral to the next fiscal year of milestones associated with the domestic development of the in-licensed product scheduled for the second half of the fiscal year, profit forecasts were also lowered.
| Item | Details |
|---|---|
| Net Sales | Cumulative second-quarter results ¥48,000 million → ¥44,800 million（-6.7%） / Full year ¥95,700 million → ¥88,700 million（-7.3%） |
| Operating profit | Cumulative second-quarter results ¥1,900 million → ¥500 million（-73.7%） / Full year ¥4,400 million → ¥2,000 million（-54.5%） |
| Ordinary income | Cumulative second-quarter results ¥2,800 million → ¥1,700 million（-39.3%） / Full year ¥6,000 million → ¥4,000 million（-33.3%） |
| Profit attributable to owners of the parent | Cumulative second-quarter results ¥8,000 million → ¥7,400 million（-7.5%） / Full year ¥14,500 million → ¥13,300 million（-8.3%） |
| Net income per share | Cumulative second-quarter results 196.77 yen and sen → 176.92 yen and sen / Full year 356.65 yen and sen → 326.97 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 11 May 2026 |
| Previous-period results | Cumulative second-quarter results Net Sales ¥45,831 million, ¥ and sen / Operating profit ¥-6,837 million, ¥ and sen / Ordinary income ¥-5,622 million, ¥ and sen / Interim net income attributable to owners of the parent ¥7,784 million, ¥ and sen / Interim net income per share ¥186.81 million, ¥ and sen / Full year Net Sales ¥97,406 million, ¥ and sen / Operating profit ¥-2,927 million, ¥ and sen / Ordinary income ¥-1,162 million, ¥ and sen / Profit attributable to owners of the parent ¥13,779 million, ¥ and sen / Net income per share ¥331.54 million, ¥ and sen |
| Reason for the revision | Because Tabuneos sales deviated significantly from plan in the first quarter, the company analyzed prescription trends and lowered its revenue forecasts for the interim period and full year. In light of the increase in the cost of sales ratio resulting from the decline in Tabuneos sales, the progress and expected expenditure of selling, general and administrative expenses, and the deferral to the next fiscal year of milestones associated with the domestic development of the in-licensed product scheduled for the second half of the fiscal year, profit forecasts were also lowered. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because Tabuneos sales fell significantly below plan in the first quarter, the company analyzed prescription trends and lowered its revenue forecasts. The reasons for revising the profit forecasts also include the increase in the cost of sales ratio resulting from the decline in Tabuneos sales, the progress and expected expenditure of selling, general and administrative expenses, and the deferral to the next fiscal year of milestones associated with the domestic development of the in-licensed product scheduled for the second half of the fiscal year.